Sinonasal melanoma: age, tumor location, and treatment modality predict outcomes

  • Pontes FSC & al.
  • Int J Oral Maxillofac Surg
  • 22 Nov 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A systematic review identifies several prognostic factors associated with survival and recurrence outcomes of patients with sinonasal melanoma.

Why this matters

  • Sinonasal melanoma is a rare cancer type, and clinicopathological and prognostic factors are poorly understood.

Key results

  • 5-year OS was 30.69%.
  • 32.1% of patients experienced recurrence.
  • Age >67.6 years (P=.0042), stage IV disease (P=.0026 vs stage IA), radiotherapy (P=.0111 vs radical surgery), recurrence (P=.0137), and distant metastasis (P=.0011) were associated with poor survival outcomes.
  • Age >67.6 years (P=.0021), male sex (P=.0051), disease stage III/IV (P=.0331), and amelanotic histological type (P=.0095) were associated with recurrence.

Study design

  • 73 publications with 439 patients with sinonasal melanoma were included.
  • Funding: None.

Limitations

  • Heterogeneity between included studies.